Incidence: 14% of soft tissue tumors, 2.5% to 10.5% of soft tissue malignant tumors, higher malignancy Age: mostly in young adults, preferable age is 20-40 years old, more males than females Site: the onset of the site is mainly in the joints of the limbs (about 80%), a few primary in the trunk, chest and abdominal wall, head and neck, rare in the viscera. Symptoms: 1, early local symptoms are not obvious, mostly painful swelling and other manifestations; 2, local masses, generally slow growth, a few can be rapidly increased within a short period of time imaging: X-ray: mainly soft tissue masses, bone changes are not obvious, there may be eccentricity or calcification near the edge of the mass MRI: T1WI: the solid part of the mass shows moderate slightly high signal, hemorrhagic foci show lamellar high signal, necrosis within the tumor T2WI: the solid part of the mass shows predominantly medium slightly high signal, as well as high signal similar to fluid, medium signal similar to or slightly higher than fat signal, and slightly low signal similar to fibrous tissue, in a lobulated fashion. Differential diagnosis: malignant fibrous histiocytoma, giant cell tumor of the tendon sheath, early synovial osteochondromatosis Treatment procedure: outpatient examination, history → X-ray → ultrasound, MRI → pathology (ultrasound-guided puncture biopsy) After diagnosis: chemotherapy 3 times (individualized) → surgery → chemotherapy 3/6 times Our chemotherapy regimen: MAID regimen – international common regimen If pulmonary metastases are present. Add vincristine. Tumor vaccine and vascular targeting drugs are also feasible to greatly improve the survival rate of patients. The 5-year survival rate for primary patients is 72%; for intrapelvic patients it is slightly lower at 65%. Warm tips: Do not underestimate the mass on your body and go to a standardized hospital in time. Do not hesitate to perform ultrasound or MRI examinations and take extra care if you find the presence of blood flow signals.